1Zahir H, Nand RA, Brown KF. Validation of methods to study the distribution and protein binding of taerolimus in human blood [J] . Journal of Pharmacological and Toxicological Methods, 2001,46(1) : 27.
2Victor W,Oelleric HM.New developments in the immunosuppressive drug monitoring ofcyclosporine, tacrolimus, and azathioprine [J ] . Clinical Biochem istry, 2001, 34(1) :9.
3Ihor B,Dawna D,Qais A. Effect of low and high fat meals on Tacrolimus absorption following 5 mg single oral doses to healthy human subjects [J]. Clin Pharmacol ,2001, 41(2) : 176.
4Napoli KL.Is Microparticle enzyme linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant Recipients[J ] . Ther Drug Monit, 2006,28(4) : 491.
5Regazzi MB, Renaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients [J ]. Ther Drug Monit, 1999, 21(1) :2.
7Borrows R, Chusney G, Loucaidou M, et al. Tacrolimus monitoring in renal transplantation: a comparison between high - performance liquid chromatography and immunoassay [J] .Transplantation Proceedings, 2005, 37(4) :1 733.
8Chena YL, Hirabayashi H, Akhtar S, et al. Simultaneous determination of three isomeric metabolites of tacrolimus(FK506) in human whole blood and plasma using high performance liquid chromatography - tandem mass spectrometry [J ] .Journal of Chromatography B, 2006,830(2) :330.
9Paul S, Rutherford DM, Taylor PJ, et al. Evaluation of microparticle enzyme immunoassay against HPLC- Mass spectrometry for the determination of whole - blood tacrolimus in heart - and lung - transplant recipients [J] . Clinical Biochemistry ,2000,33(7):558.
10Qing LZ, Simpson J. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry [J ] . Ther Drug Moni, 1997, 19(4) :470.
二级参考文献16
1Paul S, Taylor PJ,Clark A, et al. High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants[J]. Ther Drug Moni, 1997,19:694,.
2MacFariane G, Scheller D, Ersfeld D, et al. A simplified whole blood enzyme-linked immunosorbent assay (ProTrac Ⅱ) for tacrolimus (FK506) using proteolvtic extraction in place of organic solvents[J]. Ther Drug Monl , 1996,18:698.
3Firdaous L, Hassoun A, Bernard OJ, et al. HPLC-microparticle enzyme immunoassay specific for tacrolimus in whole blood of hepatic and renal transplant patients [J]. Clin Chem, 1995,41(9) : 1292.
4Friob MC, Hassoun A, Latinne D, et al. A combined HPLCELISA evaluation of FK506 in transplant patients[J ]. Transpl Proc, 1991,23 : 2750.
5Gobschior AK, Christians U, Winkler M, et al. Simplified highperformance liquid chromatograph-mass spectrometry assay for measurement of tacrolimus and its metabolites and cross validation with microparticle enzyme immunoassay [ J ]. Ther Drug Moni,1995,17:504.
6Shaw LM,Amnesey TM,Kaplan B , et al. Analytic requirements for immunosupressive drugs in clinical trials [ J ]. Ther Drug Moni, 1995,17: 577.
7Taylor J ,Jones A,Balderson GA, et al. Sensitive, specific quantitative analysis of tacrolimus (FK506) in bleod by liquid chromatography-electrospray tandem mass spectrometry [ J ]. Clin Chem, 1996,42(2) :279.
8Alak AM, Moy S, Cook M, et al. An HPLC-MS^2 assay for tacrolimus in patient blood samples correlation with results of an ELISA assay[ J ]. J Pharm Biomed Anal, 1997,16 : 7.
9Braun F, Schutz E, Christians U, et al. Pitfalls in monitoring tacrolimus (FK506) [ J ]. Ther Drug Moni , 1997,19 : 628.
10Hooff van JP. , Boots JMM, Duijnhoven van EM. , et al. Dosing and management guidelines for tacrolimus in renal transplant pa-ients[ J ]. Transpl Proc, 1999,31 : 54s.
